No Data
US Stock MarketDetailed Quotes
LGVN Longeveron
Watchlist
3.250
+0.090+2.85% Close 06/02 16:00 ET
3.2500.0000.00%
Post 16:45 ET
3.300High3.200Low13.14KVolume
3.220Open3.160Pre Close42.25KTurnover0.24%Turnover RatioLossP/E (TTM)68.52MMarket Cap8.73052wk HighLossP/E (Static)21.08MShares2.50052wk Low4.20P/B17.58MFloat Cap45.000Historical High--Dividend TTM5.41MShs Float2.500Historical Low--Div YieldTTM3.17%Amplitude3.215Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
Revenue Breakdown
Business
Unit:USD
NameYOYOperating income%
Clinical trial revenue--940K76.92%
National Institutes of Health (NIH) - grant--164K13.42%
Maryland Stem Cell Research Fund (MSCRF) - Technology Development Corporation (TEDCO) - grant--118K9.66%
News
Express News | Longeveron Price Target Announced at $12.50/Share by EF Hutton
Longeveron Coverage Assumed by EF Hutton at Buy
Longeveron Coverage Assumed by EF Hutton at Buy
EF Hutton Assumes Longeveron at Buy, Announces Price Target of $12.5
EF Hutton analyst Fozia Ahmed assumes Longeveron (NASDAQ:LGVN) with a Buy rating and announces Price Target of $12.5.
Comments
Read more